Search Results - "Hundsberger, T"

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial by Wirsching, H.-G., Tabatabai, G., Roelcke, U., Hottinger, A.F., Jörger, F., Schmid, A., Plasswilm, L., Schrimpf, D., Mancao, C., Capper, D., Conen, K., Hundsberger, T., Caparrotti, F., von Moos, R., Riklin, C., Felsberg, J., Roth, P., Jones, D.T.W., Pfister, S., Rushing, E.J., Abrey, L., Reifenberger, G., Held, L., von Deimling, A., Ochsenbein, A., Weller, M.

“…The addition of bevacizumab to temozolomide-based chemoradiotherapy (TMZ/RT → TMZ) did not prolong overall survival (OS) in patients with newly diagnosed…”
Get full text

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections by Schmitt, C., Hoefsmit, E. P., Fangmeier, T., Kramer, N., Kabakci, C., Vera González, J., Versluis, J. M., Compter, A., Harrer, T., Mijočević, H., Schubert, S., Hundsberger, T., Menzies, A. M., Scolyer, R. A., Long, G. V., French, L. E., Blank, C. U., Heinzerling, L. M.

“…Background Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related…”
Get full text

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma by Hottinger, A F, Aissa, A B, Espeli, V, Squiban, D, Dunkel, N, Vargas, M I, Hundsberger, T, Mach, N, Schaller, K, Weber, D C, Bodmer, A, Dietrich, P-Y

“…Background: Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent…”
Get full text

Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis by Zeitlberger, A. M., Putora, P. M., Hofer, S., Schucht, P., Migliorini, D., Hottinger, A. F., Roelcke, U., Läubli, H., Spina, P., Bozinov, O., Weller, M., Neidert, M. C., Hundsberger, T.

“…Background Glioblastoma is the most common malignant primary brain tumour in adults and driven by various genomic alterations. Next generation sequencing (NGS)…”
Get full text

Improving outcome measures in late onset Pompe disease: Modified Rasch‐Built Pompe‐Specific Activity scale by Kooten, Harmke A., Horton, Mike C., Wenninger, Stephan, Babačić, Haris, Schoser, Benedikt, Lefeuvre, Claire, Taouagh, Najib, Laforêt, Pascal, Segovia, Sonia, Díaz‐Manera, Jordi, Claeys, Kristl G., Mongini, Tiziana, Musumeci, Olimpia, Toscano, Antonio, Hundsberger, Thomas, Brusse, Esther, Doorn, Pieter A., Ploeg, Ans T., Beek, Nadine A. M. E., Kooten, H. A, Brusse, E., Doorn, P. A, Ploeg, A. T., Beek, N. A. M. E., Wenninger, S., Babačić, H., Schoser, B., Montagnese, F., Gracia Angarita, N., Lefeuvre, C., Taouagh, N., Laforêt, P., Béhin, A., Tard, C., Campana‐Salort, E., Sacconi, S., Solé, G., Spinazzi, M., Bouhour, F., Bouibede, F., Hamroun, D., Hogrel, J. Y., Segovia, S., Díaz‐Manera, J., Claeys, K.G., Mongini, T., Musumeci, O., Toscano, A., Hundsberger, T., Horton, M. C.

“…Background and purpose The Rasch‐Built Pompe‐Specific Activity (R‐PAct) scale is a patient‐reported outcome measure specifically designed to quantify the…”
Get full text

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma by Hottinger, A F, Ben Aissa, A, Espeli, V, Squiban, D, Dunkel, N, Vargas, M I, Hundsberger, T, Mach, N, Schaller, K, Weber, D C, Bodmer, A, Dietrich, P-Y

“…This corrects the article DOI: 10.1038/bjc.2014.209…”
Get full text

Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes by Hundsberger, T., Hottinger, A. F., Roelcke, U., Roth, P., Migliorini, D., Dietrich, P. Y., Conen, K., Pesce, G., Hermann, E., Pica, A., Gross, M. W., Brügge, D., Plasswilm, L., Weller, M., Putora, P. M.

“…Despite moderate improvements in outcome of glioblastoma after first-line treatment with chemoradiation recent clinical trials failed to improve the prognosis…”
Get full text

Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial by Korfel, A., Weller, M., Martus, P., Roth, P., Klasen, H.A., Roeth, A., Rauch, M., Hertenstein, B., Fischer, T., Hundsberger, T., Leithäuser, M., Birnbaum, T., Kirchen, H., Mergenthaler, H.-G., Schubert, J., Berdel, W., Birkmann, J., Hummel, M., Thiel, E., Fischer, L.

“…We evaluated the frequency and prognostic impact of meningeal dissemination (MD) in immunocompetent adult patients with primary central nervous system lymphoma…”
Get full text

EP-0999: Re-irradiation ± bevacizumab in recurrent or progressive HGG: retrospective analysis of 13 patients by Brügge, D, Plasswilm, L, Hundsberger, T, Weder, P

Get full text

P194. Nerve sonography guided diagnosis of painful peroneal palsies caused by intraneural ganglia – A case series by Schilg, L, Felbecker, A, Haegele-Link, S, Gers, B, Weber, J, Tettenborn, B, Hundsberger, T

“…Background Acute peroneal palsy is frequently caused by compression, trauma and surgery. Risk factors are weight loss, sitting with crossed legs, wrong…”
Get full text

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma by HAU, P, KOCH, D, JAUCH, T, KOCH, H, BOGDAHN, U, HUNDSBERGER, T, MARG, E, BAUER, B, RUDOLPH, R, RAUCH, M, BRENNER, A, RIECKMANN, P, SCHUTH, J

“…We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for…”
Get full text

P17.05 MAGIC MIRROR ON THE WALL, WHICH IS THE SHARPEST ONE OF ALL? EXTERNAL VALIDATION AND COMPARISON OF THREE DIFFERENT SCORES PREDICTING SURVIVAL AFTER REIRRADIATION OF PROGRESSIVE HIGH-GRADE GLIOMAS by Muller, K., Henke, G., Compter, I., Hundsberger, T., Kortmann, R. D., Baumert, B. G.

“…BACKGROUND: Accurate predictive scores for the survival after salvage-treatment which are based on simple clinical parameters would be beneficial for the…”
Get full text

P17.41 CLINICAL MANAGEMENT AND OUTCOME OF HISTOLOGICALLY VERIFIED ADULT BRAINSTEM GLIOMAS IN SWITZERLAND: A RETROSPECTIVE ANALYSIS OF 21 PATIENTS by Hundsberger, T., Tonder, M., Andreas, H., Brugge, D., Roelcke, U., Putora, P. M., Stupp, R., Weller, M.

“…BACKGROUND: Because of low incidence, mixed study populations and paucity of clinical and histological data, the management of adult brainstem gliomas remains…”
Get full text

Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma by Glas, M, Hundsberger, T, Stuplich, M, Wiewrodt, D, Kurzwelly, D, Nguyen-Huu, B, Rasch, K, Herrlinger, U

“…In a previous trial (NOA-01), the combination of nimustine and teniposide showed efficacy in previously untreated glioblastoma (GBM). After establishing…”
Get more information

Neurolymphomatosis as a single sign of tumor recurrence in a patient with diffuse large B-cell lymphoma of the testis by Vehoff, J, Hundsberger, T, Hitz, F, Tettenborn, B

Get full text

Spontaneous, multifocal cervical liquor leakage causing an intracranial hypotension syndrome – Case Report by Fritzsche, D, Burkhardt, C, Hundsberger, T, Tettenborn, B

Get full text

Fatal outcome in a patient suffering from statin-induced rhabdomyolysis, hypothyroidism and inclusion body myopathy by Wunnicke, K, Nitschke, St, Hundsberger, T, Tolnay, M, Tettenborn, B

Get full text

Therapy refractory Voltage-gated potassium channel antibody (VGKC-Ab) negative neuromyotonia with generalized lymphadenopathy by Nitschke, S, Hundsberger, T, Hägele-Link, S, Tettenborn, B

Get full text

P26.02.A AN IN VITRO MULTIDIMENSIONAL DRUG ASSESSMENT TOOL FOR PERSONALIZED PREDICTION OF DRUG RESPONSE AND RESISTANCE IN HUMAN GLIOBLASTOMA ORGANOIDS by Camenisch, S, Mathews, L, Hoch, T, Neidert, M, Zeitlberger, A, Hundsberger, T, Jochum, W, Vélez Char, N, Ayala, V, Wick, P

“…Abstract Glioblastoma (GBM) is a highly aggressive brain tumor treated with surgery, radiotherapy, and concomitant as well as maintenance temozolomide (TMZ)…”
Get full text

P14.82 Glioneuronal tumors - a rare tumor entity with diagnostic and therapeutic challenges: report of two cases and review of literature by Zeitlberger, A M, Neidert, M C, Velez-Char, N, Hundsberger, T

“…Abstract BACKGROUND The 2007 WHO classification of brain tumors first encompassed two new entities of glioneuronal tumors, including papillary glioneuronal…”
Get full text